Literature DB >> 18761817

Laboratory characterizations on 2007 cases of monoclonal gammopathies in East China.

Hao Wang1, Chunfang Gao, Lingling Xu, Zaixing Yang, Wenjing Zhao, Xiantao Kong.   

Abstract

Monoclonal gammopathies are characterized by the presence of monoclonal immunoglobulin in patients with or without evidence of multiple myeloma (MM), macroglobulinemia, amyloidosis (AL), or a related plasma cell proliferative disorder. This study aims to evaluate laboratory diagnostic characters of monoclonal gammopathies and investigates the correlation between monoclonal gammopathies and transforming growth factor beta1 (TGFbeta1). Immunofixation electrophoresis (IFE), serum protein electrophoresis (SPE), nephelometry and urine light chain ELISA were used for laboratory identification of monoclonal immunoglobulins. Plasma TGFbeta1 was detected with double-antibodies ELISA. Lightcycler was used for single nucleotide polymorphism (SNP) analysis. Totally 2,007 cases of monoclonal immunoglobulin (M protein) were identified in 10,682 samples. The isotypes of M protein were IgG type 47.1%, IgA 23.0%, IgM 8.7%, IgD 5.3%, free light chain kappa 6.1%, lambda 9.8%. In reference to IFE, the coherency of diagnosis was serum light chain ratio (kappa/lambda ) 94.4%, quantitation of Igs 83%, light chain quantitation 80.9%, and urine light chain ratio (kappa/lambda) 58.0%. Plasma TGFbeta1 was elevated significantly compared to normal control. The allelic frequency of codon 10 (C>T) was neither associated with the existence of the M protein nor with the M protein isotype. Monoclonal gammopathies can be identified with the combination of IFE, SPE, Igs quantitation and urine light chain determination. Although TGFbeta1, an important cytokine in immune regulation, was elevated in monoclonal gammopathies, the SNPs in coding region of TGFbeta1 gene did not confer susceptibility to the development of monoclonal gammopathies in this study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18761817      PMCID: PMC4651300          DOI: 10.1038/cmi.2008.36

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  4 in total

1.  The anion gap and routine serum protein measurements in monoclonal gammopathies.

Authors:  Karen H van Hoeven; Rosy E Joseph; William J Gaughan; Laura McBride; Elizabeth Bilotti; Ann McNeill; Linda Schmidt; Danielle Schillen; David S Siegel
Journal:  Clin J Am Soc Nephrol       Date:  2011-12       Impact factor: 8.237

2.  AL amyloidosis with IgD-lambda monoclonal gammopathy and lambda-type Bence-Jones protein: successful treatment by autologous stem cell transplantation.

Authors:  Chanhyok Sakurai-Chin; Yoshifumi Ubara; Tatsuya Suwabe; Junichi Hoshino; Tomoki Yonaha; Eiko Hasegawa; Keiichi Sumida; Rikako Hiramatsu; Masayuki Yamanouchi; Noriko Hayami; Junji Yamauchi; Naoyuki Tominaga; Naoki Sawa; Fumi Takemoto; Kazuhiro Masuoka; Kenmei Takaichi; Kenichi Oohashi
Journal:  Clin Exp Nephrol       Date:  2010-07-15       Impact factor: 2.801

3.  Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.

Authors:  H Ludwig; D Milosavljevic; N Zojer; J M Faint; A R Bradwell; W Hübl; S J Harding
Journal:  Leukemia       Date:  2012-07-17       Impact factor: 11.528

4.  [The value of serum heavy/light chain immunoassay to assess therapeutic response in patients with multiple myeloma].

Authors:  X C Yu; W Su; J L Zhuang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-04-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.